Latest filing published 27 Dec 2024 for Edgewise Therapeutics, Inc., €255k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Filings by Marc Semigran span 2 companies, the busiest being Renovacor, Inc. and Edgewise Therapeutics, Inc. We count 3 filings; the first trade dates from 24 January 2022 and the latest from 24 December 2024.
Not one of the filings records a straightforward purchase or sale on the market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Most recently, on 27 December 2024, the filings show an option exercise worth €255k in Edgewise Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations